Akoya Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Akoya Biosciences, Inc. (Nasdaq: AKYA) successfully closed its initial public offering (IPO) of 7,567,000 shares at $20.00 per share, raising approximately $151.3 million in gross proceeds. The offering included the full exercise of underwriters' option to purchase an additional 987,000 shares. Trading began on April 16, 2021, on The Nasdaq Global Select Market under the symbol "AKYA." J.P. Morgan, Morgan Stanley, Piper Sandler, and Canaccord Genuity acted as joint book-running managers. The registration statement for the offering was approved by the SEC on April 15, 2021.
- Raised approximately $151.3 million in total gross proceeds.
- Successful completion of IPO indicates strong market interest.
- Possible dilution of existing shares due to new issuance.
MARLBOROUGH, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the closing of its initial public offering of 7,567,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase 987,000 additional shares of common stock, at the initial public offering price of
J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Piper Sandler & Co., and Canaccord Genuity LLC are acting as Joint Book-Running Managers for the offering.
The offering is being made only by means of a prospectus. A copy of the final prospectus related to the offering may be obtained, when available, from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email: prospectus@psc.com.
A registration statement relating to the shares sold in this offering has been filed with, and was declared effective by, the Securities and Exchange Commission April 15, 2021. Copies of the registration statement, as amended, can be accessed through the Securities and Exchange Commission’s website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research.
Investor Contact:
David Deuchler
Gilmartin Group LLC
investors@akoyabio.com
Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com
FAQ
What was the offering size for Akoya Biosciences (AKYA)?
What was the IPO price for Akoya Biosciences (AKYA)?
When did Akoya Biosciences (AKYA) begin trading on Nasdaq?
How much gross proceeds did Akoya Biosciences raise from its IPO?
Who were the underwriters for Akoya Biosciences' IPO?
